[
    [
        {
            "time": "2018-04-23",
            "original_text": "What Analysts Recommend for Pfizer ahead of 1Q18 Earnings",
            "features": {
                "keywords": [
                    "Analysts",
                    "Pfizer",
                    "1Q18",
                    "Earnings"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "What Analysts Recommend for Pfizer ahead of 1Q18 Earnings",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-24",
            "original_text": "Eli Lilly’s 1Q18 Earnings: Neuroscience Products Portfolio",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "1Q18",
                    "Earnings",
                    "Neuroscience",
                    "Products"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "neuroscience"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly’s 1Q18 Earnings: Neuroscience Products Portfolio",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-25",
            "original_text": "Why Analysts Expect Pfizer to See Revenue Growth in 1Q18",
            "features": {
                "keywords": [
                    "Analysts",
                    "Pfizer",
                    "Revenue Growth",
                    "1Q18"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Why Analysts Expect Pfizer to See Revenue Growth in 1Q18",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-26",
            "original_text": "Eli Lilly’s 1Q18 Earnings: Oncology Products Portfolio",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "1Q18",
                    "Earnings",
                    "Oncology",
                    "Products"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly’s 1Q18 Earnings: Oncology Products Portfolio",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-27",
            "original_text": "Eli Lilly’s 1Q18 Earnings: Cardiovascular Products Portfolio",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "1Q18",
                    "Earnings",
                    "Cardiovascular",
                    "Products"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "cardiovascular"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly’s 1Q18 Earnings: Cardiovascular Products Portfolio",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-28",
            "original_text": "Leena Gandhi, M.D., Ph.D., to Lead Lilly Oncology Immuno-Oncology Medical Development",
            "features": {
                "keywords": [
                    "Leena Gandhi",
                    "Lilly",
                    "Oncology",
                    "Immuno-Oncology",
                    "Medical Development"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "oncology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Leena Gandhi, M.D., Ph.D., to Lead Lilly Oncology Immuno-Oncology Medical Development",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]